Articles by Emily Menendez
Preliminary trial data suggests that 18F-DCFPyL PSMA PET/CT combined with mpMRI may improve csPCA detection over MRI alone.
Quantitative analysis outperformed visual analysis in the prediction of outcomes for patients undergoing Lu-PSMA therapy.
18F-fluciclovine PET detected disease in more than half of the study’s patients with BCR and negative PSMA PET results.
These findings highlight the need for continued development and refinement of standardized HER2 testing methods.
Almost 30% of patients will experience recurrence while undergoing EBRT that will require ADT and salvage therapies.
The study’s major efficacy outcomes included a complete response in 78% of patients.
At 12 months, the OS rate for patients who received treatment with ipilimumab plus nivolumab was superior to SOC.
Nivolumab + ipilimumab provided a favorable landmark OS in cisplatin-ineligible patients with unresectable or metastatic UC.
The addition of ipi/nivo to LuPSMA improved PSA-PFS over 12 months in patients with mCRPC.
18F-flotufolastat-PET can help determine severe hematologic toxicity in patients with mCRPC who are treated with 177Lu.
The use of MRI-based monitoring can aid in the avoidance of repeat biopsies, and reduce the chances of undergoing surgery.
Adding one year of treatment with durvalumab to BCG can extend the time that patients live without disease recurrence.
Guidance addresses prepubic fat coverage and dose fractionation for both neoadjuvant and adjuvant settings.
Radium 223 is recommended for patients with symptomatic bone-only disease.
Patients with mRCC and primary resistant disease to nivolumab plus ipilimumab have worse survival outcomes.
Patients with ARPI-treated mCSPC and BRCA1/2 alterations experienced higher rates of disease progression.
Global shortages of BCG have led to the exploration of alternative therapies for HR non-muscle invasive bladder cancer.
[68Ga]-FAPI-PET/MRI and [18F]-FDG-PET/CT share similar diagnostic accuracy for tumor staging in patients with MIBC.
Hemi-gland cryoablation and HIFU provided acceptable and eminent functional outcomes in patients over a 5-year follow-up.
Patients with ccRCC and nccRCC with tumor thrombus have similar survival outcomes after surgical resection.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.